Yousif Capital Management LLC Buys 3,195 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Yousif Capital Management LLC raised its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 7.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 44,096 shares of the company’s stock after buying an additional 3,195 shares during the period. Yousif Capital Management LLC owned about 0.05% of Myriad Genetics worth $844,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in Myriad Genetics by 96.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,101 shares of the company’s stock valued at $34,000 after acquiring an additional 1,032 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Myriad Genetics by 21.4% in the 4th quarter. Blue Trust Inc. now owns 6,729 shares of the company’s stock worth $129,000 after purchasing an additional 1,186 shares in the last quarter. Clarus Wealth Advisors bought a new position in Myriad Genetics in the 4th quarter worth $204,000. Mutual of America Capital Management LLC lifted its position in Myriad Genetics by 8.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 15,519 shares of the company’s stock valued at $297,000 after purchasing an additional 1,167 shares in the last quarter. Finally, Inspire Investing LLC grew its holdings in Myriad Genetics by 40.8% during the third quarter. Inspire Investing LLC now owns 19,002 shares of the company’s stock valued at $305,000 after purchasing an additional 5,505 shares during the period. 99.02% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group lifted their price objective on Myriad Genetics from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $23.17.

Myriad Genetics Stock Up 1.3 %

Shares of Myriad Genetics stock opened at $19.47 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.87 and a current ratio of 2.01. Myriad Genetics, Inc. has a 52 week low of $13.82 and a 52 week high of $24.21. The stock’s 50-day simple moving average is $20.73 and its 200-day simple moving average is $19.77.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. Myriad Genetics had a negative return on equity of 8.03% and a negative net margin of 34.96%. The company had revenue of $196.60 million for the quarter, compared to analysts’ expectations of $194.80 million. During the same period in the previous year, the firm earned ($0.20) EPS. The firm’s revenue was up 10.6% compared to the same quarter last year. As a group, research analysts predict that Myriad Genetics, Inc. will post -0.36 EPS for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.